The Challenge
Inbeeo’s client was a small clinical stage pharmaceutical company exploring the clinical potential of an asset with promising efficacy across several different pathologies, including systemic lupus erythematosus, cutaneous lupus erythematosus, and dermatomyositis.
Inbeeo’s client wanted to develop and operationalise a value framework to systematically evaluate the future potential of the asset across each of the potential indications while considering not only the current landscape, but also the potential future competitors.
The Approach
Inbeeo utilized its bespoke i-vbp framework to develop a tailored model.
The model identified the value of each indication and asset of interest, enabling the testing and prioritization of scenarios across indications in the form of TPP testing.
A relative comparison of values estimates across scenarios was then conducted and findings were shared in the final recommendation.
The Impact
The custom value framework enabled our client to identify the disease attractiveness and respective asset value in each of the three indications.
Assessing the asset value helped the client identify opportunities and subsequent considerations to think about to support the asset’s future development plan.
